Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%

Healthcare

Page 1
  1. Jul 01, 2026 · 07:00 · BLCO · Routine +

    Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

    New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence

    01
  2. Jul 01, 2026 · 01:47 · APTX · Routine +

    Apotex Health receives Health Canada OK for Sevmia

    Apotex Health receives Health Canada OK for Sevmia

    02
  3. Jun 30, 2026 · 19:32 · APS · Routine +

    Aptose Biosciences Closes $6.1M Hanmi Takeover, Delisting TSX as Clinical-Stage AML Biotech Exits Public Markets

    Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical

    03
  4. Jun 30, 2026 · 19:00 · ONCO · Routine −

    Preclinical-stage PNKP inhibitor developer pivots to performance-based financing amid liquidity constraints.

    Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing

    04
  5. Jun 30, 2026 · 18:00 · ONCO · Routine +

    Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010

    Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010

    05
  6. Jun 30, 2026 · 16:19 · APTX · Routine +

    Apotex Capitalizes on GLP-1 Boom with First Canadian Generic Weight-Loss Approval Post-IPO

    Apotex first to receive Health Canada approval for SEVMIA(TM), a generic semaglutide for chronic weight management

    06
  7. Jun 30, 2026 · 08:55 · PAIN · Routine +

    Vector Science files provisional patent for magnetic transdermal peptide delivery, targeting De Novo FDA pathway amid rapid pipeline expansion.

    Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform

    07
  8. Jun 30, 2026 · 08:31 · NRX · Routine −

    Dilutive financing at a discount underscores cash burn concerns in pre-revenue exosome developer

    NurExone Announces Closing of Non-Brokered Private Placement

    08
  9. Jun 30, 2026 · 08:30 · 4151 · Routine +

    Rare disease and oncology specialist advancing lifecycle management for POTELIGEO, CRYSVITA, and KOMZIFTI while transitioning key dermatology assets in-house.

    New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sezary Syndrome

    09
  10. Jun 30, 2026 · 08:01 · APPT · Routine +

    Direct-pay specialist marketplace expands network via Emphera Health partnership to bypass insurance gatekeeping.

    Apptly's UberDoc Accelerates Growth Through Emphera Health Partnership, Adding Approximately 2,000 Specialists to the UberDoc Network

    10
  11. Jun 30, 2026 · 08:00 · 4875 · Routine +

    Clinical-stage biotech advances late-stage neurology and metabolic assets with H2 2026 data catalysts on track.

    MediciNova CEO Provides Shareholder Update

    11
  12. Jun 30, 2026 · 08:00 · AIDR · Routine +

    Rocket Doctor Enters into a Primary Care Value-Based Care Agreement in the United States, Expanding In-Network Coverage by More Than 5 Million Members

    Rocket Doctor Enters into a Primary Care Value-Based Care Agreement in the United States, Expanding In-Network Coverage by More Than 5 Million Members

    12
  13. Jun 30, 2026 · 04:27 · 4565 · Routine +

    AI-driven GPCR drug discovery platform monetizing partnerships while transitioning to a profitable specialty pharma model in APAC.

    Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

    13
  14. Jun 30, 2026 · 03:06 · VIVI · Routine +

    TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

    TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

    14
Older →